The supplement industry’s survival rate is not often discussed at conferences. Brands launch with genuine enthusiasm, a good formula, a clear market gap, and real marketing ability. Then the production side of the business introduces itself, and the story changes. The brands that make it through are not always the ones with the best products. They are often the ones that understood production before it became a crisis.
1. Successful Brands Choose Manufacturing Partners Before Finalising Formulas
The sequence that fails reliably is: develop the formula, then find someone to make it. The sequence that works is: identify the manufacturing partner first, then develop the formula within that partner’s capabilities and regulatory framework. A formula developed in isolation from manufacturing realities will encounter its limitations during scale-up, an expensive and time-consuming step at which to discover them.
Brands that consult with a nutrition contract manufacturer during formulation development rather than after it is finalised end up with products that are manufacturable, stable, and compliant from the beginning rather than products that need to be re-engineered before they can be produced at scale.
2. Failed Brands Underestimate Regulatory Complexity
Supplement regulation is more detailed, more jurisdiction-specific, and more consequential for non-compliance than most first-time founders realise before they are already operating. An ingredient that is legal and unrestricted in one market is a controlled substance in another. A label claim that is acceptable under one regulatory framework requires substantiation that the brand does not have under another.
The brands that navigate this successfully are typically working with a nutrition contract manufacturer whose in-house regulatory expertise covers the markets the brand is entering. The ones that learn about these requirements from a warning letter rather than from a manufacturing partner have a significantly more difficult time course-correcting.
3. Production Consistency Separates Brands That Scale From Those That Stall
A supplement product that performs well in the first batch but differently in the fifth has a consistency problem that will show up in customer complaints, return rates, and eventually in reviews that note the product working sometimes and not others. Batch-to-batch variation is a manufacturing quality issue, not a formulation issue. The formula does not change. What changes is how reliably the manufacturing process delivers it.
Brands that scale successfully are working with facilities that have documented process controls, equipment calibration records, and quality assurance programmes that catch deviations before they leave the facility. Brands that stall are often discovering batch variation through their customers, which is the most expensive way to receive that information.
4. Inventory Management Is a Production Decision, Not a Business Decision Made Later
The brands that tie up excessive capital in inventory they cannot move, or that run out of stock during a demand peak because minimum order quantities required more lead time than was planned, have both made production decisions that the business side of the operation is now managing the consequences of.
Working through these tradeoffs before the first production run, understanding lead times, minimum quantities, shelf life constraints, and the cost of holding inventory versus the cost of stockouts, is the conversation that happens early at successful brands and happens as a postmortem at the ones that struggled.
Conclusion
The supplement brands that succeed at production are no luckier than the ones that fail. They made better decisions earlier, about manufacturing partners, regulatory preparation, quality assurance, and inventory planning. The production side of a supplement business is where most of the risk actually lives. The brands that treat it that way from the start are the ones still operating three years in.